Andrew Hanna

Dr. Andrew Hanna

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2015 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
DBDrexell Hunter Boggs
Drexell Hunter Boggs
AHAndrew Hanna
Andrew Hanna
WBWhitney Burrows
Whitney Burrows
NHNaomi Horiba
Naomi Horiba
MSMohan Suntharalingam
Mohan Suntharalingam

31 December 2015 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
AHAndrew Hanna
Andrew Hanna
DBD. Hunter Boggs
D. Hunter Boggs
YKYoung Kwok
Young Kwok
MSMarc Simard
Marc Simard
WRWilliam F. Regine
William F. Regine
MMMinesh p Mehta
Minesh p Mehta

3 November 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
MEMark S. Etherington
Mark S. Etherington
AHAndrew Hanna
Andrew Hanna
BMBenjamin D. Medina
Benjamin D. Medina
MLMengyuan Liu
Mengyuan Liu
ATAndrew D. Tieniber
Andrew D. Tieniber
RDRonald P. DeMatteo
Ronald P. DeMatteo
γδ T cells are a rare but potent subset of T cells with pleiotropic functions. They commonly reside within tumors but the response of γδ T cells to tyrosine kinase inhibition is unknown. To address this, we studied a genetically engineered mouse model of gastrointestinal stromal tumor (GIST) driven by oncogenic Kit signaling that responds to the Kit inhibitor imatinib. At baseline, γδ T cells were antitumoral, as blockade of either γδ T-cell receptor or IL17A increased tumor weight and decreased antitumor immunity. However, imatinib therapy further stimulated intratumoral γδ T cells, as determined by flow cytometry and single-cell RNA sequencing (scRNA-seq). Imatinib expanded a highly activated γδ T-cell subset with increased IL17A production and higher expression of immune checkpoints and cytolytic effector molecules. Consistent with the mouse model, γδ T cells produced IL17A in fresh human GIST specimens, and imatinib treatment increased γδ T-cell gene signatures, as measured by bulk tumor RNA-seq. Furthermore, tumor γδ T cells correlated with survival in patients with GIST. Our findings highlight the interplay between tumor cell oncogene signaling and antitumor immune responses and identify γδ T cells as targets for immunotherapy in GIST.


3 January 2024
Verified
Other
Open access
MEMark S. Etherington
Mark S. Etherington
AHAndrew Hanna
Andrew Hanna
BMBenjamin D. Medina
Benjamin D. Medina
MLMengyuan Liu
Mengyuan Liu
ATAndrew D. Tieniber
Andrew D. Tieniber
RDRonald P. DeMatteo
Ronald P. DeMatteo
Supplemental Figure S1. (A) Alternate gating strategy for identifying γδ T cells in KitV558Δ/+ tumors by flow cytometry (B) Prevalence of γδ T cells as a percentage of T cells in KitV558Δ/+ mice across multiple anatomic compartments. (C) Percent of cells positive for IFNγ in KitV558Δ/+ tumor by flow cytometry after intracellular cytokine stimulation. (D) Histograms of flow cytometry staining for the transcription factors T-bet and EOMES in T cells from KitV558Δ/+ tumors. (E) Vγ2 expression in tumor and spleen γδ T cells from KitV558Δ/+ mice. Representative of 4 mice. Data represent mean ± SEM; p values were calculated using a two-sided Student’s t test; *, P < 0.05.

3 January 2024
Verified
Other
Open access
MEMark S. Etherington
Mark S. Etherington
AHAndrew Hanna
Andrew Hanna
BMBenjamin D. Medina
Benjamin D. Medina
MLMengyuan Liu
Mengyuan Liu
ATAndrew D. Tieniber
Andrew D. Tieniber
RDRonald P. DeMatteo
Ronald P. DeMatteo
Supplemental Figure S2. Relative expression on a per cell basis in KitV558Δ/+ tumors of (A) Trdv4 and (B) multiple genes known to be members of the SCART1+ γδ T cell phenotype. Dot plots represent scRNAseq data of γδ T cells from 6 mice as detailed in the methods section.